In general, 90–95% of PV patients and 50–60% of ET and PMF patients have Janus kinase 2 (JAK2) V617F mutations, and 3% of PV patients have JAK2 exon 12 mutations [2, 3]. The gene discussed is JAK2; the disease is essential thrombocythemia.